ANN ARBOR, MI., – November 4, 2024-  Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of advanced spider silk-based fibers, is pleased to announce the successful completion of its fourth production cycle for 2024. This achievement marks a significant milestone, with record-setting performance across nearly every tracked metric for parental silkworm lines and hybrid cocoons.

The latest production cycle delivered the largest single batch of parental line cocoons the Company has ever produced. On top of the record-setting size of this batch, Kraig Labs continues to see strong vitality and robustness.

Beyond the sheer size of this production batch, quantitative analysis of this batch demonstrated that the genetics of the BAM-1 continue to improve. This batch set new records for cocoon size, shell weight, and several other key metrics for large-scale production. These records were set not only our hybrid cocoons, but also for the parental silkworm lines, reflecting comprehensive improvements throughout the entire production process.

“The results of our fourth production cycle are outstanding, showcasing the performance and capability of our BAM-1 line,” said founder and CEO of Kraig Labs, Kim Thompson. “Our ongoing advancements in genetic engineering and silkworm rearing techniques are paying off, and these achievements underscore our ability to reliably scale up production to meet growing market demands.”

By achieving new records in both parental and hybrid silkworm metrics, the Company solidifies its leadership in the field of sustainable, high-performance fibers.

“The continuous improvement in nearly every tracked performance metric is a testament to the dedication and expertise of our team and the genetics of BAM-1,” said the Company’s COO, Jon Rice. “Our comprehensive focus on genetic robustness and cocoon yield has paid off. We are well on track for scaling our operations to multi-ton levels while maintaining the quality and performance of our spider silk materials.”

Kraig Biocraft Laboratories continues to pursue new heights in advanced biomaterials, driving innovation and setting new standards in the production of spider silk fibers.

The Company will hold an investor conference call later this month at a time to be announced in the coming weeks.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – October 21, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, today announced plans to host an investor web conference in the coming weeks. This conference will provide an in-depth review of the Company’s progress over the past twelve months in commercializing its revolutionary spider silk technology.

As part of Kraig Labs’ ongoing commitment to transparency and shareholder engagement, the upcoming conference will cover recent advancements, detailed production metrics, and critical advancements accelerating the Company’s trajectory to bring its spider silk technology to market. Attendees can expect insights into total spider silk production, the development of next-generation spider silk fibers, targeted markets for early adoption, projections for production levels in 2024, and how these innovations are set to transform the global performance materials industry.

“We are excited to share the substantial progress Kraig Labs has made this past year in scaling up our spider silk production,” said Company Founder and CEO, Kim Thompson. “This shareholder conference will provide an excellent opportunity to highlight the substantial progress made this year and how we are delivering on our commercially scalable spider silk system for textile markets.”

The Company is in the process of finalizing the details for the event, and a follow-up announcement with the confirmed date and additional information will be made available as the event approaches.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This Milestone marks the Achievement of True Commercial-scale Levels of Parental Strain Production

ANN ARBOR, Mich., – October 14, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of commercially viable spider silk, is excited to announce that its current production batch is cocooning this week. This batch is the largest-scale production run of the BAM-1 parental lines in the Company’s history.

This latest batch of silkworms is part of the Company’s ongoing expansion of its proprietary spider silk production technologies. The Company’s production team and sericulture experts have been closely monitoring this production cycle and have reported strong growth and great colony health as Kraig Labs begins the cocooning process.

“We are very pleased with the progress of our current production cycle, which is on track to deliver the largest supply of BAM-1 production hybrid eggs in the Company’s history,” said Kim Thompson, CEO and founder of Kraig Labs. “The results we are seeing reflect our team’s dedication to delivering truly cost-effective and commercially scalable spider silk production. This is a major step forward in commercializing spider silk technology, made possible by our new production center, and we look forward to utilizing this expanded production space to continue accelerating our plans for market entry.”

The Company’s silkworms have been genetically engineered to produce recombinant spider silk at a level of efficiency and cost-effectiveness that was previously unattainable. This latest production run verifies the scalability of the Company’s spider silk technology, positioning Kraig Labs to deliver commercial quantities of spider silk to its partners and customers.

With the near completion of this major production run, Kraig Labs has transitioned from a development and testing mindset to a true production focus. The results of this run will supply Kraig Labs with millions of BAM-1 production hybrids slated for commercial production.

“We are at an exciting and pivotal moment in Kraig Labs’ history,” Thompson added. “This successful production cycle is a testament to the hard work of our team and the power of our spider silk technologies. It underscores our commitment to unlocking the full potential of spider silk as an innovative material with limitless applications.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – September 30, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of commercially viable spider silk, today proudly announces the launch of its largest production cycle of its BAM-1 line. Leveraging the expanded capacity of its new production rearing center, this rearing cycle will more than double the Company’s previous single-batch caterpillar production record.

To grow production capacity and maximize the new rearing center, the Company has divided this batch into two groups. Twenty percent of this batch are BAM-1 hybrids for reeling finished silk. Eighty percent of this batch is split evenly between the two BAM-1 parental lines that will be crossbred to produce  millions of BAM-1 hybrid silkworm eggs for future production cycles.

First-generation hybrids are created by crossbreeding the two BAM-1 parental lines together. These first-generation hybrids create larger production cocoons, increased robustness, and improved reeling performance. As such, the Company maintains a small population of its BAM-1 parental lines that are raised in parallel with the BAM-1 hybrids each production cycle. The priority placed on BAM-1 parental lines for this rearing cycle was explicitly targeted to quickly ramp up first-generation BAM-1 hybrid eggs.

This record-setting production cycle highlights the Company’s ongoing commitment to scaling up the production of its advanced silk materials, bringing Kraig Labs one step closer to revolutionizing the performance materials market.

This production batch marks a significant increase in both the volume and scale of the Company’s silkworm-based spider silk manufacturing, ensuring that Kraig Labs is well-positioned to meet the needs of these broad and diverse markets.

“This milestone BAM-1 production run exemplifies our commitment to scaling the production of our unique spider silk fibers,” said Company Founder and CEO, Kim Thompson. “As we continue to break new ground in performance materials, this expanded capacity represents a key advancement toward full-scale commercial production.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – September 23, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), proudly announces the initiation of its first production cycle for the BAM-1 parental strains at its newly established production center. This new facility boasts a footprint eight times larger than its previous facility and, when fully utilized, has the capacity to support the production of 25 metric tons of spider silk per year. This transition to a larger facility marks a pivotal moment in the Company’s growth and its commitment to transforming the textile industry.

The new production center, strategically located to optimize operations and provide easy access to supporting infrastructure, is set to accelerate the Company’s capacity for high-quality, bioengineered spider silk. This production center represents a monumental leap forward in capacity, enabling Kraig Labs to meet the demand for its groundbreaking spider silk materials and solidify its leadership in bio-engineered fibers.

This facility was built to address the production space requirements for 2025 and to create a foundation for future expansion. With this proven production blueprint established, the Company anticipates building out additional production capacity in 2025 to bring additional silk production capacity online for 2026.

“We are thrilled to embark on this new chapter in Kraig Labs’ journey,” said Company Founder and CEO, Kim Thompson. “Launching this first production cycle at this greatly expanded facility is not only a testament to our team’s dedication and hard work but also a major milestone in our mission to revolutionize material science and commercialize spider silk. Our new center will significantly enhance our production capacity, allowing us to scale up and bring our innovative spider silk technologies to a broader market.”

The launch of this production cycle and the investment into the expansion of facilities underscores the Company’s commitment to innovation and excellence in the field of bioengineered materials. With the expanded rearing capabilities, Kraig Labs aims to set new benchmarks in both production capacity and product quality, strengthening its position as a leader in the advanced materials sector.

As Kraig Biocraft Laboratories embarks on this exciting new phase, the Company extends its gratitude to its partners, investors, and team members for their unwavering support. The new production center is set to play a crucial role in driving the Company’s growth and reinforcing its position as a trailblazer in bioengineered materials.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

The Company is able to report that its operations were not in a region affected by typhoon Yagi. There has been no damage to our facilities, people, or operations.

While this storm has not directly impacted our operations, we are mindful of the loss of life and damage inflicted on people in the other parts of Vietnam and Southeast Asia. Our thoughts are with those affected, and Kraig Labs has made a contribution to ongoing humanitarian relief efforts.

Our hearts and prayers are with the people of Southeast Asia.

New Facility Online and Ready for Fall Spider Silk Production

ANN ARBOR, Mich., – September 9, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has completed the second wave of its production expansion and is now transitioning spider silk manufacturing operations to its new, larger production center.

Following the overwhelming success of the spring production trials, Kraig Labs outlined a strategic investment plan to rapidly scale its production capacity, slated to take part in two waves. The first phase was completed in July, providing the necessary space for the Company to operate through the rainy season. The second and larger project was the construction of a new production center for the Company’s spider silk manufacturing operations.

Kraig Labs kicked off construction for this new production center in July. The new facility increases the Company’s rearing capacity by more than eight times its current operations. With dedicated production spaces for each BAM-1 parental line and a dedicated space for its BAM-1 hybrid hatchery, this new facility is expected to address the production space needed to meet the spider silk production schedule through 2025.

The Company is now transitioning its production operations and equipment to this new space and finalizing the installation of backup power generation systems ahead of the next spider silk production cycle slated to begin at the end of this month.

Kicking off later this month, the first production cycle in this facility will be the largest single-cycle rearing of the BAM-1 parental strains in the Company’s history. This rearing will, in turn, allow for the full utilization of this new and significantly expanded production space.

“As planned, this new facility is coming online just in time to support our fall production kick-off. The larger production center will allow us to fully leverage the supporting silk production infrastructure, maximizing the production output and bringing our spider silk manufacturing to the next level,” said Company COO Jon Rice. “This center is the latest in a series of breakthroughs for Kraig Labs in commercial scale production of spider silk in 2024.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – August 26, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has further boosted spider silk production with the introduction of new silk cocoon reeling protocols resulting in higher silk yields.

Under the guidance of renowned sericulture expert, Dr. Nirmal Kumar, the Kraig Labs production team modified the processing of its finished silk cocoons, increasing total silk yields per cocoon and improving reeling performance. These mechanical changes to the processing and handling of the Company’s spider silk cocoons resulted in a near doubling of reeling efficiency compared to the prior production runs.

“Increasing processing efficiency and cocoon yield was one of Kraig’s top three goals for increasing production,” said Company founder and CEO, Kim Thompson. “Congratulations to the production team for these dramatic improvements. We anticipated many more months of work before seeing these results. Now we can focus on increasing individual cocoon size, and overall production volumes. I believe that even further gains in possessing yield can be achieved over the next two production cycles.”

Dr. Nirmal Kumar and the Kraig Labs production team harvested the third production cycle of its proprietary spider silk cocoon last week. The BAM-1 hybrid cocoons have now been processed under the direction of Dr. Nirmal Kumar and the newly implemented enhanced protocols. In addition to finished reeling spider silk, the team has collected, analyzed, and selected the top performing BAM-1 parent line cocoons for production expansion this fall. Over the next week, selective matings of these top-performing moths will be used to create the next generation of BAM-1 parental line and BAM-1 production hybrids.

“Dr. Nirmal Kumar has evolved our operations at an incredible pace, bringing nuanced details and innovative troubleshooting that has netted outsized returns at a rapid pace,” said Company COO, Jon Rice. “These small details and tweaks in processing the finished cocoons have yielded huge improvements in finished silk yield. Undoubtedly, his continued guidance will play a major role in our continuing expansion of production.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – August 19, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has completed the third commercial spider silk production cycle. This cycle primarily focused on producing the Company’s BAM-1 recombinant spider silk hybrids, which marks the second successful commercial production cycle of the Company’s most advanced spider silk hybrids.

This production occurred during the region’s rainy season, a time of high humidity and heavy rains, which prevents most silk producers from operating. Kraig Labs actively chose to continue production during the rainy season to further challenge test the robustness and resilience of its BAM-1 hybrids. 

Operating during the rainy season helped to further optimize Kraig Labs’ silkworm colony and identify the best performers and future colony expansion. Renowned sericulture expert Dr. Nirmal Kumar is with the production team to analyzing all of the data collected during this rearing cycle and guiding the team to optimize the BAM-1 parental lines for continued success and growth of spider silk production.  

Over the next two weeks, the Company will harvest the hybrid spider silk cocoons from this production cycle and send them to local reeling facilities. This batch of cocoons will be used to further refine reeling operations, improve efficiency, and produce additional finished spider silk for use and sale in end markets.

“There is no stiffer challenge for the robustness than operating during the rainy season. Our BAM-1 hybrids demonstrated that they are ready for the worst mother nature can throw at them,” said Company COO, Jon Rice. “Our team continues to hit new production and processing milestones with the BAM-1 hybrids as the catalyst for rapid and continuous growth in our scalable and commercially sustainable spider silk production.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – August 13, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has confirmed that the material performance of its commercially produced recombinant spider silk matches the exceptional strength and toughness of the Company’s previous small batch performance testing. The results of this testing open the doors for Kraig Labs to aggressively move forward with commercial production of its proprietary recombinant spider silk.

Testing was completed last week at the Company’s R&D headquarters, pitting samples of the Company’s commercially produced spider silk against samples of mundane silk in a head-to-head test. Using a high-precision tensile testing machine, multiple samples of each silk type were tested using high-frequency data sampling, monitoring force, and displacement. Yield strength, ultimate tensile strength, and elongation data were collected and analyzed, confirming the mechanical superiority of the Company’s spider silk.

This testing confirmed that there has been no loss in strength or toughness associated with this significant growth in production scale. While these results were expected, by Kraig Labs and its key production advisor, verifying that what works in the lab also works in the field under commercial production conditions was an important milestone.

“The results of this testing confirm the performance of our production spider silk, unlocking a scalable system for commercial sustainable spider silk production,” said Company COO, Jon Rice. “Having worked with these materials for some time, we are not at all surprised by these results. We are happy to have our expectations confirmed and the added confidence to continue to aggressively move forward with our spider silk production scale-up.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com